NCT04957433 is a clinical trial of Blood Specimen in Lung Cancer, sponsored by Royal Marsden NHS Foundation Trust.

Who is sponsoring NCT04957433?

NCT04957433 is sponsored by Royal Marsden NHS Foundation Trust.

What drugs are being tested in NCT04957433?

Interventions in NCT04957433: Blood Specimen.

What condition does NCT04957433 study?

NCT04957433 studies Lung Cancer, Cancer.

Is NCT04957433 still recruiting?

NCT04957433 is currently status unknown. Last updated 18 July 2022.

Last reviewed 2022-07-18 · How we verify

NCT04957433

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

'Lung Health Check' Biomarker Study

Status unknown Last updated 18 July 2022

What this trial tests

trial testing Blood Specimen in Lung Cancer in 1,000 participants. Status unknown.

Timeline

28 September 2020

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Royal Marsden NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	28 September 2020
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Blood Specimen — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Cancer — all drugs for Cancer →

Sponsor

Royal Marsden NHS Foundation Trust

Who can join

Adults 55 to 75, any sex, with Lung Cancer or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CT screening of lung cancer offers an opportunity to diagnose early stage lung cancers which is associated with better prognosis - indeterminate results delay diagnosis whilst interval imaging is awaited to assess risk of cancer. This study will allow us to examine the potential of blood-based biomarkers to augment CT screening for lung cancer. Hypotheses 1. Blood and sputum samples can be collected in patients attending lung health checks as part of the Lung Health Check pilot in West London at fixed and mobile scanners and safely transported for processing and storage in preparation for biomarker development. 2. The biomarkers will help to identify cohorts of 1. High-risk patients in whom CT surveillance should be conducted more readily/frequently and diagnostic procedures performed earlier. 2. Low-risk patients who might need reduced surveillance intensity. 3. Patients with interstitial lung abnormalities that share similar biomarker characteristics to patients with clinically significant interstitial lung disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774

Verify or expand the search:

Other trials of Blood Specimen

Trials testing the same drug.

NCT05964504 — Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) · recruiting
NCT05287347 — Panc CA Risk Model & Biomarker Testing In High-Risk Cohort · withdrawn

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Royal Marsden NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04957433 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
Last refreshed: 18 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04957433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing